Table 1 Clinical characteristics of the patients from the Leucegene cohort, with the PRMT2low and PRMT2high groups
From: Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia
Leucegene | PRMT2low | PRMT2high | Statistical significance | |
|---|---|---|---|---|
(n = 371) | (n = 37) | (n = 37) | ||
De novo | 346 (93.3%) | 36 (97.3%) | 35 (94.6%) | |
t-AML | 25 (6.7%) | 1 (2.7%) | 2 (5.4%) | |
Sex | ||||
Male | 210 (56.6%) | 19 (51.4%) | 23 (62.2%) | |
Female | 161 (43.4%) | 18 (48.6%) | 14 (37.8%) | |
Age (years) | ||||
Median | 58 | 57 | 55 | |
Range | 17-87 | 22-82 | 18-84 | |
WBC count (x109/L) | ||||
Median | 33.2 | 14.5 | 73.4 | *** |
Range | 0.8-361.2 | 1.3-322.5 | 2.9-361.2 | |
Cytogenetic risk | ||||
Favorable | 46 (12.4%) | 4 (10.8%) | 9 (24.3%) | |
Intermediate | 206 (55.5%) | 19 (51.4%) | 22 (59.5%) | |
Adverse | 117 (31.5%) | 14 (37.8%) | 6 (16.2%) | |
FAB subtype | ||||
M0 | 23 (6.2%) | 2 (5.4%) | 4 (10.8%) | |
M1 | 103 (27.8%) | 10 (27.0%) | 14 (37.8%) | |
M2 | 50 (13.5%) | 9 (24.3%) | 7 (18.9%) | |
M4 | 56 (15.1%) | 4 (10.8%) | 4 (10.8%) | |
M5 | 63 (17%) | 5 (13.5%) | 5 (13.5%) | |
M6 | 8 (2.2%) | 1 (2.7%) | 0 | |
M7 | 2 (0.5%) | 0 | 0 | |
Not classificable | 66 (17.8%) | 6 (16.2%) | 3 (8.1%) |
